A Single Arm, Open Label Multicentre Extension Study of Bevacizumab in Patients With Solid Tumours on Study Treatment With Bevacizumab, at the End of A F. Hoffmann-La Roche and/or Genentech Sponsored Study
A Single Arm, Open Label Multicentre Extension Study of Bevacizumab in Patients With Solid Tumours on Study Treatment With Bevacizumab, at the End of A F. Hoffmann-La Roche and/or Genentech Sponsored Study
This single-arm, open-label, multicenter extension study will provide continued bevacizumab therapy to participants with solid tumors who were previously enrolled in a Roche/Genentech sponsored study and who derived benefit from the bevacizumab therapy. Participants will receive the same dose and regimen of bevacizumab as used in the previous parent trial and continue this treatment until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
Inclusion Criteria:
Exclusion Criteria:
Toronto, Ontario M5G 2M9, Canada
Frankfurt am Main, 60528, Germany
Naples, Campania 80131, Italy
Bologna, Emilia-Romagna 40138, Italy
Rome, Lazio 00152, Italy
Milan, Lombardy 20133, Italy
S. Fermo Della Battaglia (CO), Lombardy 22020, Italy
Turin, Piedmont 10126, Italy
Pisa, Tuscany 56124, Italy
Obninsk, Kaluzhskaya Region, 249034, Russia
Parktown, Johannesburg, 2193, South Africa
Seoul, 138-736, South Korea
A Coruña, 15006, Spain
Jaén, 23007, Spain